Arcus Biosciences, Inc. (RCUS) 10-K Annual Report March 2019

Ended 2018 with four molecules in clinical development, including AB928, the Company’s dual A_2aR/A_2bR receptor antagonist, which is being evaluated in several dose-escalation trials in combination with chemotherapy or AB122 (anti-PD-1 antibody)

Also ongoing are a Phase 1 trial of AB154 (anti-TIGIT antibody) in patients with advanced solid tumors, alone and in combination with AB122, as well as a trial of AB680 (CD73 inhibitor) in healthy volunteers

Ended 2018 with $259.7 million in cash and investments

Hayward, CA. – (BUSINESS WIRE) – March 5, 2019 -

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced financial results for the fourth quarter and full year 2018. The Company also provided updates on its clinical programs.

“Throughout 2018, we made substantial progress on multiple programs, ending the year with four product candidates in the clinic,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “Enrollment continues in our first three dose-escalation trials for AB928, in which we are evaluating AB928 in combination with either immunogenic chemotherapies or our anti-PD-1 antibody, AB122, across a number of tumor types. We plan to present early data on safety, pharmacokinetic/pharmacodynamic profile, biomarker analysis and clinical activity for the AB928 combinations in mid-2019. Following our IPO last year, we have a strong balance sheet, and we are well-positioned to execute on our research and clinical development plans into 2021.”

Pipeline Updates

AB928 (dual A_2aR/A_2bR antagonist)

•	The Company continues to enroll patients in the first three AB928 combination trials:

•

AB928 in combination with Doxil® in triple negative breast cancer (TNBC) and ovarian cancer

•

AB928 in combination with mFOLFOX in colorectal cancer and gastroesophageal cancer

•

AB928 in combination with AB122 in advanced solid tumors.

•	The Company expects to initiate its fourth AB928 combination trial in patients in the coming months:

•

AB928 in combination with carboplatin/pemetrexed with or without pembrolizumab in non-small cell lung cancer (NSCLC) after failing tyrosine kinase inhibitor (TKI) therapy.

AB122 (anti-PD-1 antibody)

•	The Company is enrolling the final cohort of the Phase 1 dose-escalation trial for AB122. Based on data generated to date, the Company selected 240 mg as the dose for the Q2W (every 2 weeks)

The following information was filed by Arcus Biosciences, Inc. (RCUS) on Tuesday, March 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1724521/000156459019006274/rcus-10k_20181231.htm

View differences made from one year to another to evaluate Arcus Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Arcus Biosciences, Inc..

Continue

Assess how Arcus Biosciences, Inc.'s management team is paid from their Annual Proxy

Arcus Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Arcus Biosciences, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.17: Material Contract

Exhibit 10.18: Material Contract

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: RCUS
CIK: 1724521
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-006274
Submitted to the SEC: Tue Mar 05 2019 4:16:30 PM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rcus/0001564590-19-006274.htm

Arcus Biosciences, Inc. (RCUS) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

SEC Filings

RCUS Valuations

RCUS Annual Reports

RCUS Quarterly Reports

RCUS Corporate News